Checkpoint blockade for metastatic melanoma and Merkel cell carcinoma in HIV-positive patients von Heppt, M.V., Schlaak, M., Eigentler, T.K., Kähler, K.C., Kiecker, F., Loquai, C., Meier, F., Tomsitz, D., Brenner, N., Niesert, A.C., Thonke, R., Hauschild, A., Berking, C.

Volltext

Early switch from run-in treatment with vemurafenib plus cobimetinib to atezolizumab after 3 months leads to rapid loss of tumour control in patients with advanced BRAFV600-positiv... von Livingstone, E., Gogas, H., Kandolf-Sekulovic, L., Meier, F., Eigentler, T.K., Ziemer, M., Terheyden, P.A.M., Gesierich, A.H., Herbst, R.A., Kähler, K.C., Ziogas, D.C., Mijuskovic, Z., Garzarolli, M., Garbe, C., Roesch, A., Ugurel, S., Gutzmer, R., Grob, J.J., Kiecker, F., Utikal, J., Windemuth-Kieselbach, C., Eckhardt, S., Zimmer, L., Schadendorf, D.

Volltext

Prospective evaluation of follow-up in melanoma patients in Germany – Results of a multicentre and longitudinal study von Livingstone, E, Krajewski, C, Eigentler, T.K, Windemuth-Kieselbach, C, Benson, S, Elsenbruch, S, Hauschild, A, Rompel, R, Meiss, F, Mauerer, A, Kähler, K.C, Dippel, E, Möllenhoff, K, Kilian, K, Mohr, P, Utikal, J, Schadendorf, D

Volltext

Erythema nodosum-like lesions during BRAF inhibitor therapy: Report on 16 new cases and review of the literature von Mössner, R., Zimmer, L., Berking, C., Hoeller, C., Loquai, C., Richtig, E., Kähler, K.C., Hassel, J.C., Gutzmer, R., Ugurel, S.

Volltext

Differential influence of vemurafenib and dabrafenib on patients’ lymphocytes despite similar clinical efficacy in melanoma von Schilling, B., Sondermann, W., Zhao, F., Griewank, K.G., Livingstone, E., Sucker, A., Zelba, H., Weide, B., Trefzer, U., Wilhelm, T., Loquai, C., Berking, C., Hassel, J., Kähler, K.C., Utikal, J., Al Ghazal, P., Gutzmer, R., Goldinger, S.M., Zimmer, L., Paschen, A., Hillen, U., Schadendorf, D.

Volltext

Predictive value of PD-L1 based on mRNA level in the treatment of stage IV melanoma with ipilimumab von Brüggemann, C., Kirchberger, M. C., Goldinger, S. M., Weide, B., Konrad, A., Erdmann, M., Schadendorf, D., Croner, R. S., Krähenbühl, L., Kähler, K. C., Hafner, C., Leisgang, W., Kiesewetter, F., Dummer, R., Schuler, G., Stürzl, M., Heinzerling, L.

Volltext

Actual practice of melanoma follow-up and treatment in Germany: results of a prospective, longitudinal cohort study von Livingstone, E., Eigentler, T.K., Windemuth-Kieselbach, C., Hauschild, A., Rompel, R., Trefzer, U., Nashan, D., Kilian, K., Debus, D., Kähler, K.C., Mauerer, A., Möllenhoff, K., Dippel, E., Schadendorf, D.

Volltext

Differential influence of vemurafenib and dabrafenib on patients' lymphocytes despite similar clinical efficacy in melanoma von SCHILLING, B, SONDERMANN, W, LOQUAI, C, BERKING, C, HASSEL, J, KÄHLER, K. C, UTIKAL, J, AL GHAZAL, P, GUTZMER, R, GOLDINGER, S. M, ZIMMER, L, PASCHEN, A, ZHAO, F, HILLEN, U, SCHADENDORF, D, GRIEWANK, K. G, LIVINGSTONE, E, SUCKER, A, ZELBA, H, WEIDE, B, TREFZER, U, WILHELM, T

Volltext

Hepatic arterial Fotemustine chemotherapy in patients with liver metastases from cutaneous melanoma is as effective as in ocular melanoma von Siegel, R, Hauschild, A, Kettelhack, C, Kähler, K.C, Bembenek, A, Schlag, P.M

Volltext

Alopecia due to chemotherapeutics, hedgehog inhibitors, targeted antibody therapies and immune checkpoint inhibitors : Pathogenesis, clinical picture, diagnostics and prophylaxis von Sachse, M M, Kähler, K C

Volltext

Alopezie durch Chemotherapeutika, Hedgehog-Inhibitoren, zielgerichtete Antikörpertherapien und Immuncheckpointinhibitoren: Pathogenese, Klinik, Diagnostik und Prophylaxe von Sachse, M. M., Kähler, K. C.

Volltext

1345POutcome of patients with elevated LDH treated with first-line targeted therapy (TT) or PD-1 based immune checkpoint inhibitors (ICI) von Knispel, S, Gassenmaier, M, Menzies, A M, Loquai, C, Johnson, D B, Franklin, C, Gutzmer, R, Hassel, J C, Weishaupt, C, Eigentler, T, Schummer, P, Kiecker, F, Owen, C, Schmidgen, M I, Kähler, K C, Cann, C G, Niebel, D, Mohr, P, Schadendorf, D, Zimmer, L

Volltext

Predictive value of PD-L1 based on mRNA level in the treatment of stage IV melanoma with ipilimumab von Brüggemann, C, Kirchberger, M C, Goldinger, S M, Weide, B, Konrad, A, Erdmann, M, Schadendorf, D, Croner, R S, Krähenbühl, L, Kähler, K C, Hafner, C, Leisgang, W, Kiesewetter, F, Dummer, R, Schuler, G, Stürzl, M, Heinzerling, L

Volltext

Single-agent anti-PD-1 or combined with ipilimumab in patients with mucosal melanoma: an international, retrospective, cohort study von Dimitriou, F., Namikawa, K., Reijers, I.L.M., Buchbinder, E.I., Soon, J.A., Zaremba, A., Teterycz, P., Mooradian, M.J., Armstrong, E., Nakamura, Y., Vitale, M.G., Tran, L.E., Bai, X., Allayous, C., Provent-Roy, S., Indini, A., Bhave, P., Farid, M., Kähler, K.C., Mehmi, I., Atkinson, V., Klein, O., Stonesifer, C.J., Zaman, F., Haydon, A., Carvajal, R.D., Hamid, O., Dummer, R., Hauschild, A., Carlino, M.S., Mandala, M., Robert, C., Lebbe, C., Guo, J., Johnson, D.B., Ascierto, P.A., Shoushtari, A.N., Sullivan, R.J., Cybulska-Stopa, B., Rutkowski, P., Zimmer, L., Sandhu, S., Blank, C.U., Lo, S.N., Menzies, A.M., Long, G.V.

Volltext

Moderne Behandlungsoptionen bei aktinischen Keratosen der Haut von Hauschild, A, Kähler, K C, Egberts, F

Volltext

Differential influence of vemurafenib and dabrafenib on patients’ lymphocytes despite similar clinical efficacy in melanoma von Schilling, B, Sondermann, W, Zhao, F, Griewank, K G, Livingstone, E, Sucker, A, Zelba, H, Weide, B, Trefzer, U, Wilhelm, T, Loquai, C, Berking, C, Hassel, J, Kähler, K C, Utikal, J, Al Ghazal, P, Gutzmer, R, Goldinger, S M, Zimmer, L, Paschen, A, Hillen, U, Schadendorf, D, Dermatologic Cooperative Oncology Group

Volltext

Modern treatment modalities in actinic keratoses of the skin von Hauschild, A, Kähler, K C, Egberts, F

Volltext

Differential influence of vemurafenib and dabrafenib on patients' lymphocytes despite similar clinical efficacy in melanoma von Schilling, B, Sondermann, W, Zhao, F, Griewank, K G, Livingstone, E, Sucker, A, Zelba, H, Weide, B, Trefzer, U, Wilhelm, T, Loquai, C, Berking, C, Hassel, J, Kähler, K C, Utikal, J, Al Ghazal, P, Gutzmer, R, Goldinger, S M, Zimmer, L, Paschen, A, Hillen, U, Schadendorf, D

Volltext

Hautveränderungen durch „targeted therapies von Kähler, K. C, Hauschild, A

Volltext

Hautveränderungen durch „targeted therapies: Richtige Diagnose und Therapie bei onkologischen Patienten von Kähler, K. C., Hauschild, A.

Volltext